logo

Andrew Layton, BA

home / authors / andrew-layton-ba

Articles

Site Logo

Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease

Renée J.G. Arnold, PharmD, RPh;Andrew Layton, BA;Nathan R. Rustay, PhD;Susy Chen, MD
February 21st 2017

Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).

Read More

Latest Updated Articles

Anatomy of Human Heart on medical background. 3d render - Image credit: ckybe | stock.adobe.com
Published: March 10th 2025 | Updated: March 21st 2025
Pharmacists Will Play an Essential Role in Optimizing Vutrisiran Therapy for ATTR-CM
Image credit: toeytoey | stock.adobe.com
Published: March 12th 2025 | Updated: March 18th 2025
MDMA Rejected: The Story of a Study Participant Entrenched in Ethical Violations
Blood test for graft-vs-host-disease (GVHD) -- Image credit: MdBabul | stock.adobe.com
Published: February 26th 2025 | Updated: March 14th 2025
Navigating Steroid-Refractory GVHD Treatment: A Pharmacist’s Guide to Medication Management
fda on paper texture - Image credit: Araki Illustrations | stock.adobe.com
Published: March 7th 2025 | Updated: March 10th 2025
FDA Approves Interchangeable Biosimilar to Xolair
Benjamin Franklin on US dollar surrounded by pills | Image Credit: © Cagkan - stock.adobe.com
Published: January 22nd 2025 | Updated: January 28th 2025
Reversal of Executive Order 14087 Raises Questions About Future Drug Pricing Reforms
A pregnant woman sits on a bed, holding a glass of water in one hand while preparing to take prenatal vitamins in the other. She appears thoughtful and focused on her health - Image credit: Prostock-studio | stock.adobe.com
Published: December 18th 2024 | Updated: January 2nd 2025
Study Shows Choline and Iodine Are Missing Links in Prenatal Supplements